A novel catheter ablation strategy for non‐paroxysmal atrial fibrillation combining cryoballoon, radiofrequency, and Marshall‐vein ethanol ablations

Abstract

AbstractBackgroundsCatheter ablation for non‐paroxysmal atrial fibrillation (non‐PAF) remains challenging and more effective strategy has been required to reduce postoperative arrhythmia recurrences. This study aims to investigate the efficacy and safety of a novel extensive ablation strategy for non‐PAF, that is based on a combination of cryoballoon (CBA), radiofrequency (RFA), and Marshall‐vein ethanol ablations (EA‐VOM).MethodsThe study was a single‐center, retrospective observational study. We enrolled 171 consecutive patients who underwent de‐novo catheter ablation for non‐PAF under conscious sedation with a novel extensive ablation strategy that included CBA for pulmonary vein isolation (PVI) and left atrial roof ablation (LARA), RFA for mitral isthmus (MI) ablation, superior vena cava isolation, and other linear ablations and EA‐VOM. Recurrence of atrial arrhythmias over 1 year, procedure outcomes, and procedure‐related complications were investigated.ResultsA total of 139 (81.3%) patients remained in sinus rhythm during 1‐year follow‐up. Of the 139 patients, 51 patients (29.8%) received antiarrhythmic drugs. The mean procedure time was 204 ± 45 min. PVI and LARA ablation by CBA and MI block by RFA and EA‐VOM were completed in 171 (100%) and 166 (97.1%) patients, respectively. No serious procedure‐related complications were observed except for one case of delayed pericardial effusion.ConclusionApproximately 80% of the study patients were AF‐free during 1‐year follow‐up period after a single procedure based on the novel extensive ablation strategy combining CBA, RFA, and EA‐VOM. This strategy for non‐PAF may be preferred in terms of maintenance of sinus rhythm, safety even in high‐risk patients, and relatively short procedure time.